Claims for Patent: 12,661,359

« Back to Dashboard

Summary for Patent: 12,661,359

Title:	Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders
Abstract:	The present disclosure provides a combination therapy for treating a liver disease or disorder and/or a lipid disease or disorder in a subject in need thereof. Specifically, the combination therapy comprises administration of rosuvastatin and resmetirom to a subject in need thereof.
Inventor(s):	Rebecca Taub
Assignee:	Madrigal Pharmaceuticals Inc
Application Number:	US18/263,546
Patent Claims:	1. A method of treating a fatty liver disease in a human subject in need thereof, the method comprising administering to the human subject in need thereof an oral dose of 60 mg to 100 mg of resmetirom per day, wherein the human subject in need thereof is on a rosuvastatin regimen of 5 mg to 20 mg per day. 2. The method according to claim 1, wherein the fatty liver disease is non-alcoholic steatohepatitis (NASH). 3. The method according to claim 2, wherein the oral dose of resmetirom is 60 mg per day. 4. The method according to claim 2, wherein the oral dose of resmetirom is 80 mg per day. 5. The method according to claim 2, wherein the oral dose of resmetirom is 100 mg per day. 6. The method according to claim 2, comprising administering to the subject in need thereof a pharmaceutically acceptable oral dosage form comprising Form I resmetirom. 7. The method according to claim 2, wherein the rosuvastatin regimen is 10 mg per day. 8. The method according to claim 2, comprising administering to the human subject in need thereof a gel, a tablet, a pill, or a capsule comprising the oral dose of resmetirom. 9. The method according to claim 2, comprising administering to the human subject in need thereof a tablet comprising the oral dose of resmetirom. 10. The method according to claim 3, comprising administering to the human subject in need thereof a tablet comprising the oral dose of resmetirom. 11. The method according to claim 4, comprising administering to the human subject in need thereof a tablet comprising the oral dose of resmetirom. 12. The method according to claim 5, comprising administering to the human subject in need thereof a tablet comprising the oral dose of resmetirom. 13. The method according to claim 6, wherein the pharmaceutically acceptable oral dosage form is a tablet.